A molecular portrait of high-grade ductal carcinoma in situ

Cancer Research

Volumn 75, Issue 18, 2015, Pages 3980-3990

  Abba, Martin C ^a   Gong, Ting ^b   Lu, Yue ^b   Lee, Jaeho ^b   Zhong, Yi ^b   Lacunza, Ezequiel ^a   Butti, Matias ^a   Takata, Yoko ^b   Gaddis, Sally ^b   Shen, Jianjun ^b   Estecio, Marcos R ^b,c   Sahin, Aysegul A ^c   Aldaz, C Marcelo ^b  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTOME; UNTRANSLATED RNA; UVOMORULIN; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; MESSENGER RNA; RNA; T LYMPHOCYTE ANTIGEN; TUMOR PROTEIN;

ARTICLE; BREAST CARCINOMA; BREAST EPITHELIUM; CANCER GRADING; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE COURSE; EXOME; GENE MUTATION; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; PRECANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RNA SEQUENCE; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR GROWTH; BREAST; BREAST TUMOR; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MUTATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BREAST; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CTLA-4 ANTIGEN; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; RNA, UNTRANSLATED; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTOME;

EID: 84942873875     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0506     Document Type: Article

References (54)

1. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010; 2010: 139-41.
2. Page DL, Dupont WD, Rogers LW, Jensen RA, Schuyler PA. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76: 1197-200.
3. Allred DC Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 2010; 2010: 134-8.
4. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999; 86: 429-38.
5. Mokbel K, Cutuli B. Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol 2006; 7: 756-65.
6. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853-a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006; 24: 3381-7.
7. Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 2013; 105: 701-10.
8. Marshall E. Breast cancer. Dare to do less. Science 2014; 343: 1454-6.
9. Lagios MD, Silverstein MJ. Risk of recurrence of ductal carcinoma in situ by oncotype Dx technology: some concerns. Cancer 2014; 120: 1085.
10. Formenti SC, Arslan AA, Pike MC. Re: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103: 1723.
11. Thorat MA, Parmar V, Nadkarni MS, Badwe RA. Radiation therapy for ductal carcinoma in situ: is it really worth it? J Clin Oncol 2007; 25: 461-2; author reply 462.
12. Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res 2006; 8: R61.
13. Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 1956-65.
14. Muggerud AA, Hallett M, Johnsen H, Kleivi K, Zhou W, Tahmasebpoor S, et al. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol 2010; 4: 357-68.
15. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 2011; 104: 120-7.
16. Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 2001; 93: 700-4.
17. Miron A, Varadi M, Carrasco D, Li H, Luongo L, Kim HJ, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010; 70: 5674-8.
18. Polyak K. Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010; 2010: 210-3.
19. Brenner AJ, Stampfer MR, Aldaz CM. Increased p16 expression with first senescence arrestinhuman mammary epithelial cells and extended growth capacity with p16 inactivation. Oncogene 1998; 17: 199-205.
20. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-8.
21. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-9.
22. Wang K, Li M, Hakonarson H. ANNOVAR: function alannotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
23. Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 2012; 28: 423-5.
24. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 2011; 27: 1571-2.
25. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-11.
26. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26: 139-40.
27. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010; 26: i237-45.
28. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 2003; 34: 374-8.
29. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor ofbreast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
30. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4: 2612.
31. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
32. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-21.
33. Stephens PJ, Tarpey PS, Davies H, Van Loo P, Greenman C, Wedge DC, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486: 400-4.
34. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-52.
35. Hwang ES, DeVries S, Chew KL, Moore DH II, Kerlikowske K, Thor A, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin Cancer Res 2004; 10: 5160-7.
36. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.
37. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A 2012; 109: 2802-7.
38. Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, et al. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 2014; 5: 9864-76.
39. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010; 28: 495-501.
40. Orom UA, Shiekhattar R. Noncoding RNAs and enhancers: complications of a long-distance relationship. Trends Genet 2011; 27: 433-9.
41. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-6.
42. Zhang X, Lian Z, Padden C, Gerstein MB, Rozowsky J, Snyder M, et al. A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood 2009; 113: 2526-34.
43. Persson H, Kvist A, Rego N, Staaf J, Vallon-Christersson J, Luts L, et al. Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene. Cancer Res 2011; 71: 78-86.
44. Newie I, Sokilde R, Persson H, Grabau D, Rego N, Kvist A, et al. The HER2-encoded miR-4728-3p regulates ESR1 through a non-canonical internal seed interaction. PLoS ONE 2014; 9: e97200.
45. Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, et al. An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alphapositive human breast cancer cell lines and clinical samples. FEBS J 2010; 277: 1684-94.
46. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, et al. miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol 2011; 193: 409-24.
47. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M, et al. A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008; 182: 509-17.
48. Yu Z, Xu Z, Disante G, Wright J, Wang M, Li Y, et al. miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget 2014; 5: 1083-90.
49. Tong X, Li L, Li X, Heng L, Zhong L, Su X, et al. SOX10, a novel HMG-box-containing tumor suppressor, inhibits growth and metastasis of digestive cancers by suppressing the Wnt/beta-catenin pathway. Oncotarget 2014; 5: 10571-83.
50. Fu DY, Wang ZM, Li C, Wang BL, Shen ZZ, Huang W, et al. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010; 119: 601-12.
51. Thu KL, Radulovich N, Becker-Santos DD, Pikor LA, Pusic A, Lockwood WW, et al. SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/beta-catenin signaling. Oncogene 2014; 33: 279-88.
52. Cimino-Mathews A, Subhawong AP, Elwood H, Warzecha HN, Sharma R, Park BH, et al. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Hum Pathol 2013; 44: 959-65.
53. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 2000; 405: 974-8.
54. Raman V, Tamori A, Vali M, Zeller K, Korz D, Sukumar S. HOXA5 regulates expression of the progesterone receptor. J Biol Chem 2000; 275: 26551-5.